Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 137

1.

Evaluation of 12 GWAS-drawn SNPs as biomarkers of rheumatoid arthritis response to TNF inhibitors. A potential SNP association with response to etanercept.

Ferreiro-Iglesias A, Montes A, Perez-Pampin E, Cañete JD, Raya E, Magro-Checa C, Vasilopoulos Y, Caliz R, Ferrer MA, Joven B, Carreira P, Balsa A, Pascual-Salcedo D, Blanco FJ, Moreno-Ramos MJ, Manrique-Arija S, Ordoñez MDC, Alegre-Sancho JJ, Narvaez J, Navarro-Sarabia F, Moreira V, Valor L, Garcia-Portales R, Marquez A, Gomez-Reino JJ, Martin J, Gonzalez A.

PLoS One. 2019 Feb 28;14(2):e0213073. doi: 10.1371/journal.pone.0213073. eCollection 2019.

2.

Association between concomitant csDMARDs and clinical response to TNF inhibitors in overweight patients with axial spondyloarthritis.

Hernández-Breijo B, Plasencia-Rodríguez C, Navarro-Compán V, Martínez-Feito A, Jochems A, Kneepkens EL, Wolbink GJ, Rispens T, Diego C, Pascual-Salcedo D, Balsa A.

Arthritis Res Ther. 2019 Feb 20;21(1):66. doi: 10.1186/s13075-019-1849-3.

3.

The effect of methotrexate versus other disease-modifying anti-rheumatic drugs on serum drug levels and clinical response in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors.

Martínez-Feito A, Plasencia-Rodríguez C, Navarro-Compán V, Hernández-Breijo B, González MÁ, Monjo I, Nuño L, Nozal P, Pascual-Salcedo D, Balsa A.

Clin Rheumatol. 2019 Mar;38(3):949-954. doi: 10.1007/s10067-018-4355-0. Epub 2018 Nov 6.

PMID:
30402698
4.

Specific Association of HLA-DRB1*03 With Anti-Carbamylated Protein Antibodies in Patients With Rheumatoid Arthritis.

Regueiro C, Rodriguez-Rodriguez L, Triguero-Martinez A, Nuño L, Castaño-Nuñez AL, Villalva A, Perez-Pampin E, Lopez-Golan Y, Abasolo L, Ortiz AM, Herranz E, Pascual-Salcedo D, Martínez-Feito A, Boveda MD, Gomez-Reino JJ, Martín J, Gonzalez-Escribano MF, Fernandez-Gutierrez B, Balsa A, Gonzalez-Alvaro I, Gonzalez A.

Arthritis Rheumatol. 2019 Mar;71(3):331-339. doi: 10.1002/art.40738. Epub 2019 Jan 28.

PMID:
30277011
5.

Golimumab Tapering Strategy Based on Serum Drug Levels in Patients With Spondyloarthritis.

Redondo C, Martínez-Feito A, Plasencia-Rodríguez C, Navarro-Compán V, Nuño-Nuño L, Peiteado D, Villalba A, Jochems A, Pascual-Salcedo D, Balsa A.

Arthritis Rheumatol. 2018 Aug;70(8):1356-1358. doi: 10.1002/art.40542. Epub 2018 Jul 2. No abstract available.

PMID:
29736972
6.

Validation study of genetic biomarkers of response to TNF inhibitors in rheumatoid arthritis.

Lopez-Rodriguez R, Perez-Pampin E, Marquez A, Blanco FJ, Joven B, Carreira P, Ferrer MA, Caliz R, Valor L, Narvaez J, Cañete JD, Ordoñez MDC, Manrique-Arija S, Vasilopoulos Y, Balsa A, Pascual-Salcedo D, Moreno-Ramos MJ, Alegre-Sancho JJ, Navarro-Sarabia F, Moreira V, Garcia-Portales R, Raya E, Magro-Checa C, Martin J, Gomez-Reino JJ, Gonzalez A.

PLoS One. 2018 May 7;13(5):e0196793. doi: 10.1371/journal.pone.0196793. eCollection 2018.

7.

Differential blood cellular profile in patients with moderate-to-severe psoriasis treated with classical systemic therapies: a step forward in personalized medicine.

Hernández-Breijo B, Jurado T, Rodríguez-Martín E, Martínez-Feito A, Plasencia-Rodríguez C, Balsa A, Alonso-Pacheco ML, Villar LM, Herranz-Pinto P, Pascual-Salcedo D.

Br J Dermatol. 2018 Sep;179(3):765-766. doi: 10.1111/bjd.16537. Epub 2018 Jun 21. No abstract available.

PMID:
29526036
8.

IgA anti-β2 glycoprotein I antibodies: Experience from a large center.

Vlagea A, Pascual-Salcedo D, Álvarez Doforno R, Lavilla P, Diez J, Padilla Merlano B, Cuesta MV, Gil A.

Thromb Res. 2018 Feb;162:38-43. doi: 10.1016/j.thromres.2017.12.007. Epub 2017 Dec 12.

PMID:
29274563
9.

Practical recommendations for the use of therapeutic drug monitoring of biopharmaceuticals in inflammatory diseases.

Dreesen E, Bossuyt P, Mulleman D, Gils A, Pascual-Salcedo D.

Clin Pharmacol. 2017 Oct 3;9:101-111. doi: 10.2147/CPAA.S138414. eCollection 2017. Review.

10.

Optimal concentration range of golimumab in patients with axial spondyloarthritis.

Martínez-Feito A, Plasencia-Rodriguez C, Navarro-Compán V, Jurado T, Kneepkens EL, Wolbink GJ, Martín S, Ruiz Del Agua A, Navarro R, Mezcua A, Jochems A, Peiteado D, Bonilla MG, Balsa A, Pascual-Salcedo D.

Clin Exp Rheumatol. 2018 Jan-Feb;36(1):110-114. Epub 2017 Sep 15.

PMID:
28980904
11.

Value of Measuring Anti-Carbamylated Protein Antibodies for Classification on Early Arthritis Patients.

Regueiro C, Nuño L, Ortiz AM, Peiteado D, Villalba A, Pascual-Salcedo D, Martínez-Feito A, González-Alvaro I, Balsa A, González A.

Sci Rep. 2017 Sep 20;7(1):12023. doi: 10.1038/s41598-017-09657-5.

12.

Current Practices for Therapeutic Drug Monitoring of Biopharmaceuticals in Pediatrics.

Murias S, Magallares L, Albizuri F, Pascual-Salcedo D, Dreesen E, Mulleman D.

Ther Drug Monit. 2017 Aug;39(4):370-378. doi: 10.1097/FTD.0000000000000423. Review.

PMID:
28703718
13.

Rationale for Therapeutic Drug Monitoring of Biopharmaceuticals in Inflammatory Diseases.

Paintaud G, Passot C, Ternant D, Bertolotto A, Bejan-Angoulvant T, Pascual-Salcedo D, Mulleman D.

Ther Drug Monit. 2017 Aug;39(4):339-343. doi: 10.1097/FTD.0000000000000410. Review.

PMID:
28486309
14.

Infusion reactions during infliximab treatment are not associated with IgE anti-infliximab antibodies.

van Schie KA, Ooijevaar-De Heer P, Kruithof S, Plasencia C, Jurado T, Pascual Salcedo D, Brandse JF, d'Haens GR, Wolbink GJ, Rispens T.

Ann Rheum Dis. 2017 Jul;76(7):1285-1288. doi: 10.1136/annrheumdis-2016-211035. Epub 2017 Apr 28.

PMID:
28455438
15.

Impact of immunogenicity on response to anti-TNF therapy in moderate-to-severe plaque psoriasis: results of the PREDIR study.

Ara-Martín M, Pinto PH, Pascual-Salcedo D.

J Dermatolog Treat. 2017 Nov;28(7):606-612. doi: 10.1080/09546634.2017.1296927. Epub 2017 Mar 8.

PMID:
28274164
16.

[Anti-tumor necrosis factor drug therapy: The usefulness of monitoring drug levels and anti-drug antibodies in clinical practice].

García Ruiz de Morales JM, Pascual-Salcedo D, Llinares Tello F, Valor Méndez L.

Med Clin (Barc). 2016 Nov 4;147(9):410-416. doi: 10.1016/j.medcli.2016.04.002. Epub 2016 May 20. Spanish. No abstract available.

PMID:
27216221
17.

Influence of elevated-CRP level-related polymorphisms in non-rheumatic Caucasians on the risk of subclinical atherosclerosis and cardiovascular disease in rheumatoid arthritis.

López-Mejías R, Genre F, Remuzgo-Martínez S, González-Juanatey C, Robustillo-Villarino M, Llorca J, Corrales A, Vicente E, Miranda-Filloy JA, Magro C, Tejera-Segura B, Ramírez Huaranga MA, Pina T, Blanco R, Alegre-Sancho JJ, Raya E, Mijares V, Ubilla B, Mínguez Sánchez MD, Gómez-Vaquero C, Balsa A, Pascual-Salcedo D, López-Longo FJ, Carreira P, González-Álvaro I, Rodríguez-Rodríguez L, Fernández-Gutiérrez B, Ferraz-Amaro I, Castañeda S, Martín J, González-Gay MA.

Sci Rep. 2016 Aug 18;6:31979. doi: 10.1038/srep31979.

18.

Serum tocilizumab trough concentration can be used to monitor systemic IL-6 receptor blockade in patients with rheumatoid arthritis: a prospective observational cohort study.

Kneepkens EL, van den Oever I, Plasencia CH, Pascual-Salcedo D, de Vries A, Hart M, Nurmohamed MT, Balsa A, Rispens T, Wolbink G.

Scand J Rheumatol. 2017 Mar;46(2):87-94. doi: 10.1080/03009742.2016.1183039. Epub 2016 Jul 20.

PMID:
27440258
19.

Comparing a tapering strategy to the standard dosing regimen of TNF inhibitors in rheumatoid arthritis patients with low disease activity.

Plasencia C, Wolbink G, Krieckaert CL, Kneepkens EL, Turk S, Jurado T, Martínez-Feito A, Navarro-Compán V, Bonilla G, Villalba A, Peiteado D, Nuño L, Martín-Mola E, Nurmohamed MT, van der Kleij D, Rispens T, Pascual-Salcedo D, Balsa A.

Clin Exp Rheumatol. 2016 Jul-Aug;34(4):655-62. Epub 2016 May 19.

PMID:
27214767
20.

Monitoring serum etanercept levels in juvenile idiopathic arthritis: a pilot study.

Alcobendas R, Rodríguez-Vidal A, Pascual-Salcedo D, Murias S, Remesal A, Diego C, Merino R.

Clin Exp Rheumatol. 2016 Sep-Oct;34(5):955-956. Epub 2016 Apr 28. No abstract available.

PMID:
27156742
21.

Antibodies to infliximab in Remicade-treated rheumatic patients show identical reactivity towards biosimilars.

Ruiz-Argüello MB, Maguregui A, Ruiz Del Agua A, Pascual-Salcedo D, Martínez-Feito A, Jurado T, Plasencia C, Balsa A, Llinares-Tello F, Rosas J, Torres N, Martínez A, Nagore D.

Ann Rheum Dis. 2016 Sep;75(9):1693-6. doi: 10.1136/annrheumdis-2015-208684. Epub 2016 Mar 10.

PMID:
26965981
22.

Effect of Infliximab Dose Increase in Rheumatoid Arthritis at Different Trough Concentrations: A Cohort Study in Clinical Practice Conditions.

Plasencia C, Jurado T, Villalba A, Peitedado D, Casla MT, Nuño L, Bonilla MG, Martínez-Feito A, Martín-Mola E, Pascual-Salcedo D, Balsa A.

Front Med (Lausanne). 2015 Oct 8;2:71. doi: 10.3389/fmed.2015.00071. eCollection 2015.

23.

Comparing Tapering Strategy to Standard Dosing Regimen of Tumor Necrosis Factor Inhibitors in Patients with Spondyloarthritis in Low Disease Activity.

Plasencia C, Kneepkens EL, Wolbink G, Krieckaert CL, Turk S, Navarro-Compán V, L'Ami M, Nurmohamed MT, van der Horst-Bruinsma I, Jurado T, Diego C, Bonilla G, Villalba A, Peiteado D, Nuño L, van der Kleij D, Rispens T, Martín-Mola E, Balsa A, Pascual-Salcedo D.

J Rheumatol. 2015 Sep;42(9):1638-46. doi: 10.3899/jrheum.141128. Epub 2015 Jul 15.

PMID:
26178279
24.

Comparison study of two commercially available methods for the determination of golimumab and anti-golimumab antibody levels in patients with rheumatic diseases.

Martín S, del Agua AR, Torres N, Pascual-Salcedo D, Plasencia C, Ruiz-Argüello B, Martínez A, Navarro R, Nagore D.

Clin Chem Lab Med. 2015 Oct;53(11):e297-9. doi: 10.1515/cclm-2015-0266. No abstract available.

PMID:
25945722
25.

Replication of PTPRC as genetic biomarker of response to TNF inhibitors in patients with rheumatoid arthritis.

Ferreiro-Iglesias A, Montes A, Perez-Pampin E, Cañete JD, Raya E, Magro-Checa C, Vasilopoulos Y, Sarafidou T, Caliz R, Ferrer MA, Joven B, Carreira P, Balsa A, Pascual-Salcedo D, Blanco FJ, Moreno-Ramos MJ, Fernández-Nebro A, Ordóñez MC, Alegre-Sancho JJ, Narváez J, Navarro-Sarabia F, Moreira V, Valor L, García-Portales R, Marquez A, Martin J, Gómez-Reino JJ, Gonzalez A.

Pharmacogenomics J. 2016 Apr;16(2):137-40. doi: 10.1038/tpj.2015.29. Epub 2015 Apr 21.

PMID:
25896535
26.

Rheumatoid arthritis response to treatment across IgG1 allotype - anti-TNF incompatibility: a case-only study.

Montes A, Perez-Pampin E, Navarro-Sarabia F, Moreira V, de la Serna AR, Magallares B, Vasilopoulos Y, Sarafidou T, Fernández-Nebro A, Ordóñez Mdel C, Narváez J, Cañete JD, Marquez A, Pascual-Salcedo D, Joven B, Carreira P, Moreno-Ramos MJ, Caliz R, Ferrer MA, Garcia-Portales R, Blanco FJ, Magro C, Raya E, Valor L, Alegre-Sancho JJ, Balsa A, Martin J, Plant D, Isaacs J, Morgan AW, Barton A, Wilson AG; Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate (BRAGGSS), Gómez-Reino JJ, Gonzalez A.

Arthritis Res Ther. 2015 Mar 18;17:63. doi: 10.1186/s13075-015-0571-z.

27.

Lack of association between JAK3 gene polymorphisms and cardiovascular disease in Spanish patients with rheumatoid arthritis.

García-Bermúdez M, López-Mejías R, Genre F, Castañeda S, Corrales A, Llorca J, González-Juanatey C, Ubilla B, Miranda-Filloy JA, Pina T, Gómez-Vaquero C, Rodríguez-Rodríguez L, Fernández-Gutiérrez B, Balsa A, Pascual-Salcedo D, López-Longo FJ, Carreira P, Blanco R, Martín J, González-Gay MA.

Biomed Res Int. 2015;2015:318364. doi: 10.1155/2015/318364. Epub 2015 Mar 1.

28.

Antiphospholipid antibodies correlate with stroke severity and outcome in patients with antiphospholipid syndrome.

Rodríguez-Sanz A, Martínez-Sánchez P, Prefasi D, Fuentes B, Pascual-Salcedo D, Blanco-Bañares MJ, Díez-Tejedor E.

Autoimmunity. 2015;48(5):275-81. doi: 10.3109/08916934.2014.988329. Epub 2014 Dec 1.

PMID:
25434364
29.

Golimumab trough levels, antidrug antibodies and clinical response in patients with rheumatoid arthritis treated in daily clinical practice.

Kneepkens EL, Plasencia C, Krieckaert CL, Pascual-Salcedo D, van der Kleij D, Nurmohamed MT, López-Casla MT, Wieringa R, Rispens T, Wolbink G.

Ann Rheum Dis. 2014 Dec;73(12):2217-9. doi: 10.1136/annrheumdis-2014-205983. Epub 2014 Sep 26. No abstract available.

PMID:
25261580
30.

Osteoprotegerin CGA haplotype protection against cerebrovascular complications in anti-CCP negative patients with rheumatoid arthritis.

Genre F, López-Mejías R, García-Bermúdez M, Castañeda S, González-Juanatey C, Llorca J, Corrales A, Ubilla B, Miranda-Filloy JA, Pina T, Gómez-Vaquero C, Rodríguez-Rodríguez L, Fernández-Gutiérrez B, Balsa A, Pascual-Salcedo D, López-Longo FJ, Carreira P, Blanco R, González-Álvaro I, Martín J, González-Gay MA.

PLoS One. 2014 Sep 3;9(9):e106823. doi: 10.1371/journal.pone.0106823. eCollection 2014.

31.

Anti-adalimumab antibodies in paediatric rheumatology patients: a pilot experience.

Murias S, Alcobendas R, Pascual-Salcedo D, Remesal A, Peralta J, Merino R.

Rheumatology (Oxford). 2014 Nov;53(11):2124-6. doi: 10.1093/rheumatology/keu305. Epub 2014 Aug 7. No abstract available.

PMID:
25102859
32.

Interferon regulatory factor 5 genetic variants are associated with cardiovascular disease in patients with rheumatoid arthritis.

García-Bermúdez M, López-Mejías R, Genre F, Castañeda S, Llorca J, González-Juanatey C, Corrales A, Ubilla B, Miranda-Filloy JA, Pina T, Gómez-Vaquero C, Rodríguez-Rodríguez L, Fernández-Gutiérrez B, Balsa A, Pascual-Salcedo D, López-Longo FJ, Carreira P, Blanco R, Martín J, González-Gay MA.

Arthritis Res Ther. 2014 Jul 10;16(4):R146. doi: 10.1186/ar4608.

33.

Lack of association between ABO, PPAP2B, ADAMST7, PIK3CG, and EDNRA and carotid intima-media thickness, carotid plaques, and cardiovascular disease in patients with rheumatoid arthritis.

López-Mejías R, Genre F, García-Bermúdez M, Ubilla B, Castañeda S, Llorca J, González-Juanatey C, Corrales A, Miranda-Filloy JA, Pina T, Gómez-Vaquero C, Rodríguez-Rodríguez L, Fernández-Gutiérrez B, Balsa A, Pascual-Salcedo D, López-Longo FJ, Carreira P, Blanco R, Martín J, González-Gay MA.

Mediators Inflamm. 2014;2014:756279. doi: 10.1155/2014/756279. Epub 2014 Mar 25.

34.

Lack of validation of genetic variants associated with anti-tumor necrosis factor therapy response in rheumatoid arthritis: a genome-wide association study replication and meta-analysis.

Márquez A, Ferreiro-Iglesias A, Dávila-Fajardo CL, Montes A, Pascual-Salcedo D, Perez-Pampin E, Moreno-Ramos MJ, García-Portales R, Navarro F, Moreira V, Magro C, Caliz R, Ferrer MA, Alegre-Sancho JJ, Joven B, Carreira P, Balsa A, Vasilopoulos Y, Sarafidou T, Cabeza-Barrera J, Narvaez J, Raya E, Cañete JD, Fernández-Nebro A, Ordóñez Mdel C, de la Serna AR, Magallares B, Gomez-Reino JJ, González A, Martín J.

Arthritis Res Ther. 2014 Mar 11;16(2):R66. doi: 10.1186/ar4504.

35.

Single-nucleotide polymorphisms at the 9p21.3 genomic region not associated with the risk of cardiovascular disease in patients with rheumatoid arthritis.

García-Bermúdez M, López-Mejías R, Genre F, Castañeda S, González-Juanatey C, Llorca J, Corrales A, Miranda-Filloy JA, Pina T, Gómez-Vaquero C, Rodríguez-Rodríguez L, Fernández-Gutiérrez B, Pascual-Salcedo D, Balsa A, López-Longo FJ, Carreira P, Blanco R, González-Álvaro I, Martín J, González-Gay MA.

Tissue Antigens. 2013 Dec;82(6):405-9. doi: 10.1111/tan.12227. Epub 2013 Oct 15.

PMID:
24498997
36.

Confirmation of -174G/C interleukin-6 gene promoter polymorphism as a genetic marker predicting antitumor necrosis factor treatment outcome.

Dávila-Fajardo CL, Márquez A, Pascual-Salcedo D, Moreno Ramos MJ, García-Portales R, Magro C, Alegre-Sancho JJ, Balsa A, Cabeza-Barrera J, Raya E, Martín J.

Pharmacogenet Genomics. 2014 Jan;24(1):1-5. doi: 10.1097/FPC.0000000000000013.

PMID:
24253594
37.

SMAD3 rs17228212 gene polymorphism is associated with reduced risk to cerebrovascular accidents and subclinical atherosclerosis in anti-CCP negative Spanish rheumatoid arthritis patients.

García-Bermúdez M, López-Mejías R, Genre F, Castañeda S, González-Juanatey C, Llorca J, Corrales A, Miranda-Filloy JA, Rueda-Gotor J, Gómez-Vaquero C, Rodríguez-Rodríguez L, Fernández-Gutiérrez B, Pascual-Salcedo D, Balsa A, López-Longo FJ, Carreira P, Blanco R, González-Álvaro I, Martín J, González-Gay MA.

PLoS One. 2013 Oct 21;8(10):e77695. doi: 10.1371/journal.pone.0077695. eCollection 2013. Erratum in: PLoS One. 2013;8(11). doi:10.1371/annotation/3fc037c1-2585-4d2b-a781-e04ab7b3bfeb.

38.

The 11q23.3 genomic region-rs964184-is associated with cardiovascular disease in patients with rheumatoid arthritis.

López-Mejías R, Genre F, García-Bermúdez M, Castañeda S, González-Juanatey C, Llorca J, Corrales A, Miranda-Filloy JA, Rueda-Gotor J, Gómez-Vaquero C, Rodríguez-Rodríguez L, Fernández-Gutiérrez B, Balsa A, Pascual-Salcedo D, López-Longo FJ, Carreira P, Blanco R, González-Álvaro I, Martín J, González-Gay MA.

Tissue Antigens. 2013 Nov;82(5):344-7. doi: 10.1111/tan.12217.

PMID:
24131021
39.

The immunogenicity to the first anti-TNF therapy determines the outcome of switching to a second anti-TNF therapy in spondyloarthritis patients.

Plasencia C, Pascual-Salcedo D, García-Carazo S, Lojo L, Nuño L, Villalba A, Peiteado D, Arribas F, Díez J, López-Casla MT, Martín-Mola E, Balsa A.

Arthritis Res Ther. 2013 Jul 26;15(4):R79. doi: 10.1186/ar4258.

40.

Association of CD247 polymorphisms with rheumatoid arthritis: a replication study and a meta-analysis.

Teruel M, McKinney C, Balsa A, Pascual-Salcedo D, Rodriguez-Rodriguez L, Ortiz AM, Gómez-Vaquero C, González-Gay MA, Smith M, Witte T, Merriman T, Lie BA, Martin J.

PLoS One. 2013 Jul 5;8(7):e68295. doi: 10.1371/journal.pone.0068295. Print 2013.

41.

Reply to: «understanding the immunogenicity concept».

Balsa A, Plasencia C, Pascual-Salcedo D.

Reumatol Clin. 2013 Jul-Aug;9(4):252-3. doi: 10.1016/j.reuma.2013.03.004. Epub 2013 Jun 6. English, Spanish. No abstract available.

42.

The timing of serum infliximab loss, or the appearance of antibodies to infliximab (ATI), is related with the clinical activity in ATI-positive patients with rheumatoid arthritis treated with infliximab.

Plasencia Ch, Pascual-Salcedo D, Alcocer P, Bonilla MG, Villalba A, Peiteado D, Arribas F, Díez J, Lopez-Casla MT, Martín-Mola E, Balsa A.

Ann Rheum Dis. 2013 Nov;72(11):1888-90. doi: 10.1136/annrheumdis-2013-203353. Epub 2013 Jun 5. No abstract available.

PMID:
23740237
43.

Calprotectin in rheumatoid arthritis : association with disease activity in a cross-sectional and a longitudinal cohort.

García-Arias M, Pascual-Salcedo D, Ramiro S, Ueberschlag ME, Jermann TM, Cara C, Martín-Mola E, Balsa A.

Mol Diagn Ther. 2013 Feb;17(1):49-56. doi: 10.1007/s40291-013-0016-9.

PMID:
23329363
44.

CARD8 rs2043211 (p.C10X) polymorphism is not associated with disease susceptibility or cardiovascular events in Spanish rheumatoid arthritis patients.

García-Bermúdez M, López-Mejías R, González-Juanatey C, Corrales A, Castañeda S, Ortiz AM, Miranda-Filloy JA, Gómez-Vaquero C, Fernández-Gutiérrez B, Balsa A, Pascual-Salcedo D, Blanco R, Llorca J, Martín J, González-Gay MA.

DNA Cell Biol. 2013 Jan;32(1):28-33. doi: 10.1089/dna.2012.1836. Epub 2012 Oct 22.

45.

The TT genotype of the STAT4 rs7574865 polymorphism is associated with high disease activity and disability in patients with early arthritis.

Lamana A, Balsa A, Rueda B, Ortiz AM, Nuño L, Miranda-Carus ME, Gonzalez-Escribano MF, Lopez-Nevot MA, Pascual-Salcedo D, Martin J, González-Álvaro I.

PLoS One. 2012;7(8):e43661. doi: 10.1371/journal.pone.0043661. Epub 2012 Aug 24.

46.

NFKB1-94ATTG ins/del polymorphism (rs28362491) is associated with cardiovascular disease in patients with rheumatoid arthritis.

López-Mejías R, García-Bermúdez M, González-Juanatey C, Castañeda S, Miranda-Filloy JA, Gómez-Vaquero C, Fernández-Gutiérrez B, Balsa A, Pascual-Salcedo D, Blanco R, González-Álvaro I, Llorca J, Martín J, González-Gay MA.

Atherosclerosis. 2012 Oct;224(2):426-9. doi: 10.1016/j.atherosclerosis.2012.06.008. Epub 2012 Jun 13.

PMID:
22742859
47.

Association study of MIA3 rs17465637 polymorphism with cardiovascular disease in rheumatoid arthritis patients.

García-Bermúdez M, López-Mejías R, González-Juanatey C, Corrales A, Castañeda S, Miranda-Filloy JA, Gómez-Vaquero C, Fernández-Gutiérrez B, Balsa A, Pascual-Salcedo D, Blanco R, González-Álvaro I, Llorca J, Martín J, González-Gay MA.

DNA Cell Biol. 2012 Aug;31(8):1412-7. doi: 10.1089/dna.2012.1672. Epub 2012 May 11.

PMID:
22577832
48.

Influence of immunogenicity on the efficacy of longterm treatment of spondyloarthritis with infliximab.

Plasencia C, Pascual-Salcedo D, Nuño L, Bonilla G, Villalba A, Peiteado D, Díez J, Nagore D, del Agua AR, Moral R, Martin-Mola E, Balsa A.

Ann Rheum Dis. 2012 Dec;71(12):1955-60. doi: 10.1136/annrheumdis-2011-200828. Epub 2012 May 6.

PMID:
22563028
49.

NPSR1 gene is associated with reduced risk of rheumatoid arthritis.

Robledo G, González-Gay MA, Fernández-Gutiérrez B, Lamas JR, Balsa A, Pascual-Salcedo D, Castañeda S, Blanco R, González-Alvaro I, García A, Raya E, Gómez-Vaquero C, Delgado M, Martín J.

J Rheumatol. 2012 Jun;39(6):1166-70. doi: 10.3899/jrheum.111205. Epub 2012 May 1.

PMID:
22548958
50.

Antiphosphatidylserine/prothrombin antibodies (aPS/PT) as potential markers of antiphospholipid syndrome.

Vlagea A, Gil A, Cuesta MV, Arribas F, Diez J, Lavilla P, Pascual-Salcedo D.

Clin Appl Thromb Hemost. 2013 Jun;19(3):289-96. doi: 10.1177/1076029612437578. Epub 2012 Mar 2.

PMID:
22387581

Supplemental Content

Loading ...
Support Center